Layered hydrogen titanate nanowires were synthesized from TiO2 via an alkaline−hydrothermal process and subsequent acid treatment. The average diameter of as-prepared nanowires is about 100 nm with a uniform interlayer spacing of 0.81 nm. The framework of this hydrogen titanate nanowires holds the composition of H2Ti3O7 as determined by thermogravimetric analysis. The nanostructured electrode made from these nanowires shows large lithium intercalation capacity (reversible lithium intercalation with Li0.71H2/3TiO7/3), high discharge/charge rate capability, and excellent cycling stability, as revealed by galvanostatically charge/discharge cycling tests. The detailed cyclic voltammetric investigation, however, indicates that the hydrogen titanate nanowires show pseudocapacitive characteristic during the Li+ insertion process. The novel electrochemical properties of hydrogen titanate nanowires are attributed to the open layered structure with a much larger interlayer spacing than normal intercalation compounds for commercial lithium ion batteries. The layered hydrogen titanate nanowires with unique electrochemical performance may become a promising lithium intercalation material for high-energy rechargeable lithium ion batteries and electrochemical supercapacitors.

The introduction of immune checkpoint inhibitors has demonstrated significant improvements in survival for subsets of cancer patients. However, they carry significant and sometimes life-threatening toxicities. Prompt prediction and monitoring of immune toxicities have the potential to maximise the benefits of immune checkpoint therapy. Herein, we develop a digital nanopillar SERS platform that achieves real-time single cytokine counting and enables dynamic tracking of immune toxicities in cancer patients receiving immune checkpoint inhibitor treatment - broader applications are anticipated in other disease indications. By analysing four prospective cytokine biomarkers that initiate inflammatory responses, the digital nanopillar SERS assay achieves both highly specific and highly sensitive cytokine detection down to attomolar level. Significantly, we report the capability of the assay to longitudinally monitor 10 melanoma patients during immune inhibitor blockade treatment. Here, we show that elevated cytokine concentrations predict for higher risk of developing severe immune toxicities in our pilot cohort of patients.

Highly sensitive, multiplexed detection of soluble cancer protein biomarkers can facilitate early cancer screening as well as enable real-time monitoring of patients' sensitivity and resistance to therapy. Current technologies for detection of soluble cancer protein biomarkers, e.g., enzyme-linked immunosorbent assay, however, suffer from limited sensitivity, as well as the requirement of expensive monoclonal antibodies, which undergo the quality variability. Herein, we propose a sensitive, cheap, and robust surface-enhanced Raman scattering technology to detect a panel of soluble cancer protein biomarkers, including soluble programmed death 1 (sPD-1), soluble programmed death-ligand 1 (sPD-L1) and soluble epithermal growth factor receptor (sEGFR), which are related to disease progression and treatment efficacy. In this assay, gold-silver alloy nanoboxes that have strong Raman signal enhancement capability were used as plasmonic nanostructures to facilitate highly sensitive detection. In addition, nanoyeast single-chain variable fragments were utilized as mAb alternatives to allow specific and stable protein capture performance. We successfully detected sPD-1, sPD-L1, and sEGFR with a limit of detection of 6.17 pg/mL, 0.68 pg/mL, and 69.86 pg/mL, respectively. We further tested the detection of these three soluble cancer protein biomarkers in human serum and achieved recovery rates between 82.99% and 101.67%. We believe our novel platform that achieves sensitive, multiplexed, and specific detection of soluble cancer protein biomarkers could greatly benefit cancer treatment and improve patient outcome.

No abstract